EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the substantiation of health claims related to β-hydroxy β-methylbutyrate monohydrate (HMB) alone or in combination with α-ketoisocaproic acid (KIC) and reduction of muscle tissue damage during exercise (ID 1577, 1584), increase in lean body mass (ID 1579, 1582, 1583), increase in muscle strength (ID 1578, 1583, 1587), increase in endurance performance (ID 1580, 1581), skeletal muscle tissue repair (ID 1586) and faster recovery from muscle fatigue after exercise (ID 1576, 1585) pursuant to Article 13(1) of Regulation (EC) No 1924/2006.

EFSA Publication

Link to article, DOI: 10.2903/j.efsa.2011.2227

Publication date: 2011

Document Version
Publisher’s PDF, also known as Version of record

Link back to DTU Orbit

Citation (APA):
EFSA Publication (2011). EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the substantiation of health claims related to β-hydroxy β-methylbutyrate monohydrate (HMB) alone or in combination with α-ketoisocaproic acid (KIC) and reduction of muscle tissue damage during exercise (ID 1577, 1584), increase in lean body mass (ID 1579, 1582, 1583), increase in muscle strength (ID 1578, 1583, 1587), increase in endurance performance (ID 1580, 1581), skeletal muscle tissue repair (ID 1586) and faster recovery from muscle fatigue after exercise (ID 1576, 1585) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. European Food Safety Authority. the EFSA Journal No. 2227 https://doi.org/10.2903/j.efsa.2011.2227
SCIENTIFIC OPINION

Scientific Opinion on the substantiation of health claims related to β-hydroxy β-methylbutyrate monohydrate (HMB) alone or in combination with α-ketoisocapric acid (KIC) and reduction of muscle tissue damage during exercise (ID 1577, 1584), increase in lean body mass (ID 1579, 1582, 1583), increase in muscle strength (ID 1578, 1583, 1587), increase in endurance performance (ID 1580, 1581), skeletal muscle tissue repair (ID 1586) and faster recovery from muscle fatigue after exercise (ID 1576, 1585) pursuant to Article 13(1) of Regulation (EC) No 1924/2006

EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)\textsuperscript{2, 3}

European Food Safety Authority (EFSA), Parma, Italy

SUMMARY

Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and Allergies was asked to provide a scientific opinion on a list of health claims pursuant to Article 13 of Regulation (EC) No 1924/2006. This opinion addresses the scientific substantiation of health claims in relation to β-hydroxy β-methylbutyrate monohydrate (HMB) alone or in combination with α-ketoisocapric acid (KIC) and reduction of muscle tissue damage during exercise, increase in lean body mass, increase in muscle strength, increase in endurance performance, skeletal muscle tissue repair and faster recovery from muscle fatigue after exercise. The scientific substantiation is based on the information provided by the Member States in the consolidated list of Article 13 health claims and references that EFSA has received from Member States or directly from stakeholders.

The food constituent that is the subject of the health claims is HMB, either alone or in combination with KIC. The Panel considers that HMB either alone or in combination with KIC is sufficiently characterised.


\textsuperscript{2} Panel members: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ilnes Golly, Hannu Korhonen, Pagona Lagiou, Martinus Løvik, Rosangela Marchelli, Ambroise Martin, Bevan Moseley, Monika Neuhäuser-Berthold, Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Stephan Strobel, Inge Tetens, Daniel Tomé, Hendrik van Loveren and Hans Verhagen. Correspondence: nda@efsa.europa.eu

\textsuperscript{3} Acknowledgement: The Panel wishes to thank for the preparatory work on this scientific opinion: The members of the Working Group on Claims: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ilnes Golly, Marina Heinonen, Hannu Korhonen, Martinus Løvik, Ambroise Martin, Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Inge Tetens, Hendrik van Loveren and Hans Verhagen. The members of the Claims Sub-Working Group on Weight Management/Satiety/Glucose and Insulin Control/Physical Performance: Kees de Graaf, Joanne Harrold, Mette Hansen, Mette Kristensen, Anders Sjödin and Inge Tetens.

Suggested citation: EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the substantiation of health claims related to β-hydroxy β-methylbutyrate monohydrate (HMB) alone or in combination with α-ketoisocapric acid (KIC) and reduction of muscle tissue damage during exercise (ID 1577, 1584), increase in lean body mass (ID 1579, 1582, 1583), increase in muscle strength (ID 1578, 1583, 1587), increase in endurance performance (ID 1580, 1581), skeletal muscle tissue repair (ID 1586) and faster recovery from muscle fatigue after exercise (ID 1576, 1585) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal 2011;9(6):2227. [23 pp.]. doi:10.2903/j.efsa.2011.2227. Available online: www.efsa.europa.eu/efsajournal

© European Food Safety Authority, 2011
Reduction of muscle tissue damage during exercise

The claimed effects are “minimize muscle protein breakdown” and “HMB and exercise induced muscle breakdown”. The target population is assumed to be adults performing resistance exercise. In the context of the proposed wordings and the references provided, the Panel assumes that the claimed effects relate to the reduction of damage to muscle tissue during exercise. The Panel considers that reduction of muscle tissue damage during exercise is a beneficial physiological effect.

In weighing the evidence, the Panel took into account that although one small randomised controlled trial with methodological limitations reported a significant effect of HMB in combination with KIC on surrogate measures of muscle damage during resistance training, one meta-analysis of randomised controlled trials, which included five studies and eight intervention arms, did not show an effect of HMB supplementation on muscle tissue damage during exercise.

On the basis of the data presented, the Panel concludes that a cause and effect relationship has not been established between the consumption of HMB, either alone or in combination with KIC, and reduction of muscle tissue damage during exercise.

Increase in lean body mass

The claimed effects are “increasing mass”, “HMB and lean body mass”, and “HMB and training adaptations”. The target population is assumed to be physically active individuals in the general population. In the context of the proposed wordings, the Panel assumes that the claimed effects refer to an increase in lean body mass relative to body fat mass. The Panel considers that an increase in lean body mass is a beneficial physiological effect.

In weighing the evidence, the Panel took into account that a meta-analysis of ten randomised controlled trials, and one additional randomised controlled trial not included in the meta-analysis, did not show a significant effect of HMB consumption on lean body mass during training compared to placebo.

On the basis of the data presented, the Panel concludes that a cause and effect relationship has not been established between the consumption of HMB, either alone or in combination with KIC, and increase in lean body mass.

Increase in muscle strength

The claimed effects are “increasing strength”, “HMB and training adaptations”, and “HMB and changes in muscle strength during training”. The target population is assumed to be adults performing resistance training to improve muscle strength. In the context of the proposed wordings, the Panel assumes that the claimed effects refer to an increase in muscle strength. The Panel considers that an increase in muscle strength is a beneficial physiological effect.

In weighing the evidence, the Panel took into account that the results from a meta-analysis of randomised controlled trials with respect to the effect of HMB consumption on muscle strength are inconsistent, that no significant effect of HMB consumption on muscle strength was shown in the target population for the claim, and that no evidence for a mechanism by which HMB could exert the claimed effect was provided.

On the basis of the data presented, the Panel concludes that a cause and effect relationship has not been established between the consumption of HMB, either alone or in combination with KIC, and increase in muscle strength.
Increase in endurance performance

The claimed effects are “increasing exercise lactate threshold and VO$_2$ peak”, and “HMB and aerobic metabolism”. The target population is assumed to be adults performing endurance exercise. In the context of the proposed wordings and clarifications provided by Member States, the Panel assumes that the claimed effects refer to an increase in endurance performance. The Panel considers that increase in endurance performance is a beneficial physiological effect.

No references which addressed the effects of HMB supplementation in humans on measures of endurance performance, and from which conclusions could be drawn for the scientific substantiation of the claim, were provided.

On the basis of the data presented, the Panel concludes that a cause and effect relationship has not been established between the consumption of HMB, either alone or in combination with KIC, and increase in endurance performance.

Skeletal muscle tissue repair

The claimed effect is “HMB and normal muscle repair”. The target population is assumed to be adults performing resistance exercise. In the context of the proposed wordings, the Panel assumes that the claimed effect refers to the rebuilding of structural protein within skeletal muscle tissue after exercise which has caused muscle damage. The Panel considers that skeletal muscle tissue repair is a beneficial physiological effect.

No references which addressed the effects of HMB supplementation in humans on measures of skeletal muscle tissue repair were provided.

On the basis of the data presented, the Panel concludes that a cause and effect relationship has not been established between the consumption of HMB, either alone or in combination with KIC, and skeletal muscle tissue repair.

Faster recovery from muscle fatigue after exercise

The claimed effects are “sport exercise recovery” and “HMB and muscle recovery after training”. The target population is assumed to be adults performing strenuous exercise. The Panel assumes that the claimed effects refer to muscle fatigue recovery after exercise. The Panel considers that faster recovery from muscle fatigue after exercise is a beneficial physiological effect.

In weighing the evidence, the Panel took into account that the one human intervention study provided from which conclusions could be drawn for the scientific substantiation of the claim did not show an effect of HMB on faster recovery from muscle fatigue after exercise.

On the basis of the data presented, the Panel concludes that a cause and effect relationship has not been established between the consumption of HMB, either alone or in combination with KIC, and faster recovery from muscle fatigue after exercise.

KEYWORDS

β-hydroxy β-methylbutyrate monohydrate, α-ketoisocaproic acid, HMB, KIC, muscle, strength, endurance, repair, exercise, health claims.
TABLE OF CONTENTS

Summary .................................................................................................................................................. 1
Table of contents...................................................................................................................................... 4
Background as provided by the European Commission ........................................................................ 5
Terms of reference as provided by the European Commission ................................................................. 5
EFSA Disclaimer...................................................................................................................................... 5
Information as provided in the consolidated list....................................................................................... 6
Assessment ................................................................................................................................................. 6
1. Characterisation of the food/constituent ......................................................................................... 6
   2. Relevance of the claimed effect to human health................................................................. 6
      2.1. Reduction of muscle tissue damage during exercise (ID 1577, 1584) ......................... 6
      2.2. Increase in lean body mass (ID 1579, 1582, 1583) ............................................... 7
      2.3. Increase in muscle strength (ID 1578, 1583, 1587) .............................................. 7
      2.4. Increase in endurance performance (ID 1580, 1581) ............................................ 7
      2.5. Skeletal muscle tissue repair (ID 1586) .................................................................... 7
      2.6. Faster recovery from muscle fatigue after exercise (ID 1576, 1585) ..................... 7
3. Scientific substantiation of the claimed effect ................................................................................ 8
   3.1. Reduction of muscle tissue damage during exercise (ID 1577, 1584) ......................... 8
   3.2. Increase in lean body mass (ID 1579, 1582, 1583) ............................................... 9
   3.3. Increase in muscle strength (ID 1578, 1583, 1587) .............................................. 10
   3.4. Increase in endurance performance (ID 1580, 1581) ............................................ 10
   3.5. Skeletal muscle tissue repair (ID 1586) .................................................................... 11
   3.6. Faster recovery from muscle fatigue after exercise (ID 1576, 1585) ..................... 11
Conclusions ............................................................................................................................................. 11
Documentation provided to EFSA ..................................................................................................... 13
References ............................................................................................................................................. 13
Appendices ............................................................................................................................................. 15
Glossary and Abbreviations .............................................................................................................. 23
BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION

See Appendix A

TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION

See Appendix A

EFSA DISCLAIMER

See Appendix B
INFORMATION AS PROVIDED IN THE CONSOLIDATED LIST

The consolidated list of health claims pursuant to Article 13 of Regulation EC (No) 1924/2006 submitted by Member States contains main entry claims with corresponding conditions of use and literature for similar health claims. EFSA has screened all health claims contained in the original consolidated list of Article 13 health claims which was received by EFSA in 2008 using six criteria established by the NDA Panel to identify claims for which EFSA considered sufficient information had been provided for evaluation and those for which more information or clarification was needed before evaluation could be carried out. The clarifications which were received by EFSA through the screening process have been included in the consolidated list. This additional information will serve as clarification to the originally provided information. The information provided in the consolidated list for the health claims which are the subject of this opinion is tabulated in Appendix C.

ASSESSMENT

1. Characterisation of the food/constituent

The food constituent that is the subject of the health claims is “HMB (β-hydroxy β-methylbutyrate monohydrate)” and “HMB and HMB/KIC combinations”.

From the information provided, the Panel assumes that the food constituent that is the subject of the health claims is HMB, either alone or in combination with α-ketoisocaproic acid (KIC).

β-Hydroxy β-methylbutyric acid (HMB), or β-hydroxy β-methylbutyrate, is a metabolite of the amino acid leucine. HMB can be synthesised in the human body (about 0.2-0.4 g/day) and is usually available in supplements as a calcium salt. KIC is also an intermediate metabolite of leucine. Both HMB and KIC can be measured in food by established methods.

The Panel considers that the food constituent, either HMB alone or in combination with KIC, which is the subject of the health claims, is sufficiently characterised.

2. Relevance of the claimed effect to human health

2.1. Reduction of muscle tissue damage during exercise (ID 1577, 1584)

The claimed effects are “minimize muscle protein breakdown” and “HMB and exercise induced muscle breakdown”. The Panel assumes that the target population is adults performing resistance exercise.

In the context of the proposed wordings and the references provided, the Panel assumes that the claimed effects relate to the reduction of damage to muscle tissue during exercise.

The Panel considers that reduction of muscle tissue damage during exercise is a beneficial physiological effect.

---


2.2.  Increase in lean body mass (ID 1579, 1582, 1583)

The claimed effects are “increasing mass”, “HMB and lean body mass”, and “HMB and training adaptations”. The Panel assumes that the target population is physically active individuals in the general population.

In the context of the proposed wordings, the Panel assumes that the claimed effects refer to an increase in lean body mass relative to body fat mass.

The Panel considers that an increase in lean body mass is a beneficial physiological effect.

2.3.  Increase in muscle strength (ID 1578, 1583, 1587)

The claimed effects are “increasing strength”, “HMB and training adaptations”, and “HMB and changes in muscle strength during training”. The Panel assumes that the target population is adults performing resistance training to improve muscle strength.

In the context of the proposed wordings, the Panel assumes that the claimed effects refer to an increase in muscle strength. In sports, muscle strength is sometimes a limiting factor for physical performance.

The Panel considers that an increase in muscle strength is a beneficial physiological effect.

2.4.  Increase in endurance performance (ID 1580, 1581)

The claimed effects are “increasing exercise lactate threshold and VO₂ peak”, and “HMB and aerobic metabolism”. The Panel assumes that the target population is adults performing endurance exercise.

In the context of the proposed wordings and clarifications provided by Member States, the Panel assumes that the claimed effects refer to an increase in endurance performance. Endurance performance relates to the ability to complete certain tasks with higher intensity, faster, or with a higher power output when performing long-term exercise.

The Panel considers that an increase in endurance performance is a beneficial physiological effect.

2.5.  Skeletal muscle tissue repair (ID 1586)

The claimed effect is “HMB and normal muscle repair”. The Panel assumes that the target population is adults performing resistance exercise.

In the context of the proposed wordings, the Panel assumes that the claimed effect refers to the rebuilding of structural protein within skeletal muscle tissue after exercise which has caused muscle damage.

The Panel considers that skeletal muscle tissue repair is a beneficial physiological effect.

2.6.  Faster recovery from muscle fatigue after exercise (ID 1576, 1585)

The claimed effects are “sport exercise recovery” and “HMB and muscle recovery after training”. The Panel assumes that the target population is adults performing strenuous exercise.

The Panel assumes that the claimed effects refer to muscle fatigue recovery after exercise.
Fatigue can be defined as the loss of peak force or power output. Therefore, muscle fatigue recovery can be defined as the regain of maximal muscle strength or muscle power after performance of strenuous exercise which has induced muscle fatigue.

The Panel considers that faster recovery from muscle fatigue after exercise is a beneficial physiological effect.

3. Scientific substantiation of the claimed effect

Some of the references provided for the scientific substantiation of the claims evaluated in this opinion were studies and narrative reviews which addressed the effects of HMB on outcomes (e.g., fat metabolism, hepatic and renal function, and cardiovascular system function) unrelated to the claimed effects, or which did not include original data for the scientific substantiation of the claim. The Panel considers that no conclusions can be drawn from these references for the scientific substantiation of the claims.

A meta-analysis of randomised controlled trials (RCTs) (Rowlands and Thomson, 2009) on the effects of HMB on outcomes of body composition, muscle strength and muscle damage included the majority of the publications submitted, and from which conclusions could be drawn for the scientific substantiation of the claims. The meta-analysis included 10 RCTs with a parallel design and one RCT with a cross-over design (with one-week washout between interventions). In these trials (17 intervention arms), 12 intervention arms assessed measures of muscle strength, 16 intervention arms provided body composition estimates, and eight intervention arms reported on muscle damage assessed by creatine kinase (CK) concentrations. The meta-analysis comprised 394 trained (n=259) and untrained (n=135) weight lifters on resistance training for 5±6 h/week (range 3-20 h/week), and interventions lasting 3-9 weeks. The HMB dose in all but two studies was 3.0 g/day (range 1.5-6.0 g/day).

Another meta-analysis of RCTs on the effects of HMB supplementation on lean body mass and strength during resistance training, and which included a literature search from 1967 to 2001, was provided (Nissen and Sharp, 2003). This meta-analysis included only seven RCTs on HMB (and 9 intervention arms), all of which were included in the meta-analysis by Rowlands and Thomson (2009). The Panel considers that this meta-analysis does not provide evidence for the scientific substantiation of the claims in addition to that of the meta-analysis by Rowlands and Thomson (2009).

3.1. Reduction of muscle tissue damage during exercise (ID 1577, 1584)

In the meta-analysis by Rowlands and Thomson (2009), a total of five studies, including eight effect estimates, addressed the effects of HMB supplementation on muscle damage during resistance training by means of blood concentrations of CK as a marker of muscle membrane damage (Jówko et al., 2001; Kreider et al., 1999; Kreider et al., 2000; Nissen et al., 1996; Panton et al., 2000). All intervention arms used doses of HMB of 3.0 g/day except one (i.e. 1.5 g/day). Five arms used untrained subjects whereas three used trained subjects. All subjects were young males (87 in the intervention and 88 in the control group). No significant effect of HMB consumption on CK concentrations was observed compared to placebo.

Two studies, which addressed the effect of HMB on measures of muscle damage, and which were not included in the meta-analysis, were also provided (Knitter et al., 2000; van Someren et al., 2005).

In the cross-over RCT by van Someren et al. (2005), six non resistance trained male subjects performed an exercise protocol designed to induce muscle damage on the dominant or non-dominant arm on two separate occasions. Subjects consumed HMB in combination with KIC (3.0 g HMB and 0.3 g KIC, daily) and placebo (3.0 g corn flour) given in three equal doses during the day, for 14 days.
prior to exercise. The order of the interventions was randomised. One repetition maximum (1RM), plasma CK activity, delayed onset muscle soreness (DOMS), limb girth, and range of motion (ROM) were determined pre-exercise, at 1 h, 24 h, 48 h, and 72 h post-exercise. The Panel notes that the primary outcome of the study was not identified, that no power calculations were performed, and that no control for multiplicity of analyses was applied. HMB and KIC supplementation significantly attenuated the CK response compared to placebo (p<0.05). The Panel considers that limited conclusions can be drawn from this study for the scientific substantiation of the claim.

In the RCT by Knitter et al. (2000), subjects (n=16, 8 males) were paired according to their 2-mile run times and past running experience. Each pair was randomly assigned a treatment of either HMB (3.0 g/day) or placebo (rice maltodextrin). After six weeks of daily training and supplementation, all subjects participated in a prolonged run (20-km course). CK and lactate dehydrogenase (LDH) activities were measured before and after the run to assess muscle damage. Three subjects from the placebo group withdrew from the study, and data analyses were performed in the sample of completers only (n=5 placebo, n=8 HMB). Power calculations were not performed. The Panel notes that all drop outs belonged to the placebo group, and that drop outs (and therefore the breaking of the initial group matching by training status) were not taken into account in data analysis. The Panel considers that no conclusions can be drawn from this study for the scientific substantiation of the claim.

In weighing the evidence, the Panel took into account that although one small RCT with methodological limitations reported a significant effect of HMB in combination with KIC on surrogate measures of muscle damage during resistance training, one meta-analysis of RCTs which included five studies and eight intervention arms did not show an effect of HMB supplementation on muscle tissue damage during exercise.

The Panel concludes that a cause and effect relationship has not been established between the consumption of HMB, either alone or in combination with KIC, and reduction of muscle tissue damage during exercise.

### 3.2. Increase in lean body mass (ID 1579, 1582, 1583)

Ten of the 11 RCTs considered in the meta-analysis by Rowlands and Thomson (2009), and which included 16 intervention arms, assessed the effects of HMB supplementation on lean body mass and reported size estimates. Body composition was assessed by skin fold thickness in three trials (Gallagher et al., 2000; Panton et al., 2000; Ransone et al., 2003), by bioelectrical impedance analysis (BIA) in two trials (Jówko et al., 2001; Thomson et al., 2009), by total body electrical conductivity (TOBEC) in one trial (Nissen et al., 1996), and by dual-energy x-ray absorptiometry (DXA) in four trials (Kreider et al., 1999; Kreider et al., 2000; Slater et al., 2001; Vukovich et al., 2001). No significant effect of HMB on changes in fat-free mass was observed in either trained (mean=0.8 %, 90 % CI -0.4 % to 2 %) or untrained (mean=0.9 %, 90 % CI -0.2 % to 2 %) subjects. The Panel notes that skin fold thickness, BIA and TOBEC may not be as reliable methods as DXA to assess changes in body composition in short-term intervention studies. The Panel also notes that none of the studies which assessed changes in lean body mass using DXA found a significant effect of HMB compared to placebo.

An additional RCT, which assessed the effects of HMB supplementation on lean body mass and which was not included in the meta-analysis by Rowlands and Thomson (2009), was provided (Lamboley et al., 2007). College students were randomly assigned to consume either HMB (3 g/day; n=8, 4 men) or placebo (placebo not reported; n=8, 4 men) for a 5-week supplementation period during which they underwent interval training three times a week on a treadmill. Body composition was assessed by DXA before and after training. No significant differences between groups were observed with respect to changes in body composition, including lean body mass.
In weighing the evidence, the Panel took into account that a meta-analysis of ten RCTs, and one additional RCT not included in the meta-analysis, did not show a significant effect of HMB consumption on lean body mass during training compared to placebo.

The Panel concludes that a cause and effect relationship has not been established between the consumption of HMB, either alone or in combination with KIC, and increase in lean body mass.

3.3. Increase in muscle strength (ID 1578, 1583, 1587)

Ten of the 11 RCTs considered in the meta-analysis by Rowlands and Thomson (2009), and which included 14 intervention arms, assessed the effects of HMB supplementation on measures of overall, upper and lower body muscular strength. The strength measure used was 1RM in seven studies (Gallagher et al., 2000; Jówko et al., 2001; Kreider et al., 1999; Panton et al., 2000; Ransone et al., 2003; Thomson et al., 2009; Vukovich and Dreifort, 2001), 3RM in two studies (O'Connor and Crowe, 2003; Slater et al., 2001) and a strength index, calculated as the average weight lifted to failure (4-6 repetitions) during three sets multiplied by the number of repetitions the weight was lifted, in one study (Nissen et al., 1996). There was a small but statistically significant effect of HMB on overall average muscle strength when all studies and subjects were combined (mean=3.7 %, 90 % CI 1.3 % to 6.1 %). This effect was due to the significant changes observed in untrained individuals (mean=6.6 %, 90 % CI 0.9 % to 2.3 %), particularly in lower body strength (mean=9.9 %, 90 % CI 4 % to 15.8 %). No significant changes in muscle strength were observed in the upper body for untrained lifters, or for trained lifters in overall, upper body or lower body strength. No explanation for the differential effects of HMB supplementation observed in trained vs. untrained subjects, or in upper vs. lower body strength in untrained subjects, has been provided. The Panel notes that the results from this meta-analysis with respect to the effect of HMB consumption on muscle strength are inconsistent. The Panel also notes that no significant effect of HMB consumption on muscle strength was shown in the target population (i.e. active individuals who are performing resistance training to improve muscle strength) for the claim.

An effect of HMB on protein turnover leading to an increase in lean body mass, and an effect of HMB on the reduction of skeletal muscle damage during exercise, have been hypothesised as the mechanisms by which HBM could improve muscle strength. However, the Panel notes that no evidence has been provided for any of these mechanisms (see sections 3.1 and 3.2).

In weighing the evidence, the Panel took into account that the results from a meta-analysis of RCTs with respect to the effect of HMB consumption on muscle strength are inconsistent, that no significant effect of HMB consumption on muscle strength was shown in the target population for the claim, and that no evidence for a mechanism by which HMB could exert the claimed effect was provided.

The Panel concludes that a cause and effect relationship has not been established between the consumption of HMB, either alone or in combination with KIC, and increase in muscle strength.

3.4. Increase in endurance performance (ID 1580, 1581)

Two of the human intervention studies provided assessed the effects of HMB on measures of maximal oxygen consumption (VO2,max), on ventilatory threshold or on the onset of blood lactate accumulation (Lamboley et al., 2007; Vukovich and Dreifort, 2001), but the studies did not include any measure of endurance performance. The Panel considers that no conclusions can be drawn from these references for the scientific substantiation of the claim.

In a RCT by O’Connor and Crowe (2003), the effects of a 6-week oral supplementation with HMB (3.0 g/day) vs. a mixture of HMB and creatine monohydrate (3.0 g/day HMB plus 3.0 g/day creatine) on aerobic and anaerobic capacity, peak power and total work during a cycling test in highly trained
rugby players were assessed. The control group was self-selected and received no treatment. The Panel notes that randomisation and blinding were only applied to subjects assigned to the two intervention groups. No statistically significant effect of HMB on peak power or total work was observed compared to the control group. The Panel notes the important limitations of the study design, and considers that no conclusions can be drawn for the scientific substantiation of the claim.

The Panel concludes that a cause and effect relationship has not been established between the consumption of HMB, either alone or in combination with KIC, and increase in endurance performance.

3.5. **Skeletal muscle tissue repair (ID 1586)**

No references addressing the effects of HMB supplementation in humans on measures of skeletal muscle tissue repair were provided.

The Panel concludes that a cause and effect relationship has not been established between the consumption of HMB, either alone or in combination with KIC, and skeletal muscle tissue repair.

3.6. **Faster recovery from muscle fatigue after exercise (ID 1576, 1585)**

In the RCT by Paddon-Jones et al. (2001), non resistance trained male subjects were randomly assigned to consume 40 mg/kg body weight per day of HMB (n=8) or placebo (maltodextrin calcium carbonate, n=9) for six days prior to a bout of 24 maximal isokinetic eccentric contractions of the elbow flexors, and this protocol continued throughout post testing. Muscle soreness, upper arm girth, and torque measures were assessed pre-exercise, 15 min post-exercise, and 1, 2, 3, 4, 7, and 10 days post-exercise. Power calculations were not performed. No pre-test differences between HMB and control groups were observed, and both groups performed a similar amount of eccentric work during the main eccentric exercise bout. HMB supplementation had no effect on swelling, muscle soreness, or torque following the damaging eccentric exercise bout. The Panel notes that this study does not show an effect of HMB on faster recovery from muscle fatigue after exercise.

No other references which addressed the effects of HMB supplementation in humans on measures of muscle fatigue recovery after exercise were provided.

In weighing the evidence, the Panel took into account that the one human intervention study provided from which conclusions could be drawn for the scientific substantiation of the claim did not show an effect of HMB on faster recovery from muscle fatigue after exercise.

The Panel concludes that a cause and effect relationship has not been established between the consumption of HMB, either alone or in combination with KIC, and faster recovery from muscle fatigue after exercise.

**CONCLUSIONS**

On the basis of the data presented, the Panel concludes that:

- The food constituent, HMB either alone or in combination with KIC, which is the subject of the health claims, is sufficiently characterised.
β-Hydroxy β-methylbutyrate monohydrate (HMB) alone or in combination with α-ketoisocaproic acid (KIC) related health claims

Reduction of muscle tissue damage during exercise (ID 1577, 1584)

- The claimed effects are “minimize muscle protein breakdown” and “HMB and exercise induced muscle breakdown”. The target population is adults performing resistance exercise. Reduction of muscle tissue damage during exercise is a beneficial physiological effect.

- A cause and effect relationship has not been established between the consumption of HMB, either alone or in combination with KIC, and reduction of muscle tissue damage during exercise.

Increase in lean body mass (ID 1579, 1582, 1583)

- The claimed effects are “increasing mass”, “HMB and lean body mass”, and “HMB and training adaptations”. The target population is assumed to be physically active individuals in the general population. Increase in lean body mass is a beneficial physiological effect.

- A cause and effect relationship has not been established between the consumption of HMB, either alone or in combination with KIC, and increase in lean body mass.

Increase in muscle strength (ID 1578, 1583, 1587)

- The claimed effects are “increasing strength”, “HMB and training adaptations”, and “HMB and changes in muscle strength during training”. The target population is assumed to be adults performing resistance training to improve muscle strength. Increase in muscle strength is a beneficial physiological effect.

- A cause and effect relationship has not been established between the consumption of HMB, either alone or in combination with KIC, and increase in muscle strength.

Increase in endurance performance (ID 1580, 1581)

- The claimed effects are “increasing exercise lactate threshold and VO₂ peak”, and “HMB and aerobic metabolism”. The target population is assumed to be adults performing endurance exercise. An increase in endurance performance is a beneficial physiological effect.

- A cause and effect relationship has not been established between the consumption of HMB, either alone or in combination with KIC, and increase in endurance performance.

Skeletal muscle tissue repair (ID 1586)

- The claimed effect is “HMB and normal muscle repair”. The target population is assumed to be adults performing resistance exercise. Skeletal muscle tissue repair is a beneficial physiological effect.

- A cause and effect relationship has not been established between the consumption of HMB, either alone or in combination with KIC, and skeletal muscle tissue repair.

Faster recovery from muscle fatigue after exercise (ID 1576, 1585)

- The claimed effects are “sport exercise recovery” and “HMB and muscle recovery after training”. The target population is assumed to be adults performing strenuous exercise. It is assumed that the claimed effects refer to muscle fatigue recovery after exercise. Faster recovery from muscle fatigue after exercise is a beneficial physiological effect.
• A cause and effect relationship has not been established between the consumption of HMB, either alone or in combination with KIC, and faster recovery from muscle fatigue.

**DOCUMENTATION PROVIDED TO EFSA**


**REFERENCES**


β-Hydroxy β-methylbutyrate monohydrate (HMB) alone or in combination with α-ketoisocapric acid (KIC) related health claims


Appendices

Appendix A

Background and Terms of Reference as Provided by the European Commission

The Regulation 1924/2006 on nutrition and health claims made on foods6 (hereinafter "the Regulation") entered into force on 19th January 2007.

Article 13 of the Regulation foresees that the Commission shall adopt a Community list of permitted health claims other than those referring to the reduction of disease risk and to children's development and health. This Community list shall be adopted through the Regulatory Committee procedure and following consultation of the European Food Safety Authority (EFSA).

Health claims are defined as "any claim that states, suggests or implies that a relationship exists between a food category, a food or one of its constituents and health".

In accordance with Article 13 (1) health claims other than those referring to the reduction of disease risk and to children's development and health are health claims describing or referring to:

a) the role of a nutrient or other substance in growth, development and the functions of the body; or

b) psychological and behavioural functions; or

c) without prejudice to Directive 96/8/EC, slimming or weight-control or a reduction in the sense of hunger or an increase in the sense of satiety or to the reduction of the available energy from the diet.

To be included in the Community list of permitted health claims, the claims shall be:

(i) based on generally accepted scientific evidence; and

(ii) well understood by the average consumer.

Member States provided the Commission with lists of claims as referred to in Article 13 (1) by 31 January 2008 accompanied by the conditions applying to them and by references to the relevant scientific justification. These lists have been consolidated into the list which forms the basis for the EFSA consultation in accordance with Article 13 (3).

Issues that need to be considered

Importance and Pertinence of the Food7

Foods are commonly involved in many different functions8 of the body, and for one single food many health claims may therefore be scientifically true. Therefore, the relative importance of food e.g. nutrients in relation to other nutrients for the expressed beneficial effect should be considered: for functions affected by a large number of dietary factors it should be considered whether a reference to a single food is scientifically pertinent.

---

6 OJ L12, 18/01/2007
7 The term 'food' when used in this Terms of Reference refers to a food constituent, the food or the food category.
8 The term 'function' when used in this Terms of Reference refers to health claims in Article 13(1)(a), (b) and (c).
β-Hydroxy β-methylbutyrate monohydrate (HMB) alone or in combination with α-ketoisocaproic acid (KIC) related health claims

It should also be considered if the information on the characteristics of the food contains aspects pertinent to the beneficial effect.

SUBSTANTIATION OF CLAIMS BY GENERALLY ACCEPTABLE SCIENTIFIC EVIDENCE

Scientific substantiation is the main aspect to be taken into account to authorise health claims. Claims should be scientifically substantiated by taking into account the totality of the available scientific data, and by weighing the evidence, and shall demonstrate the extent to which:

(a) the claimed effect of the food is beneficial for human health,

(b) a cause and effect relationship is established between consumption of the food and the claimed effect in humans (such as: the strength, consistency, specificity, dose-response, and biological plausibility of the relationship),

(c) the quantity of the food and pattern of consumption required to obtain the claimed effect could reasonably be achieved as part of a balanced diet,

(d) the specific study group(s) in which the evidence was obtained is representative of the target population for which the claim is intended.

EFSA has mentioned in its scientific and technical guidance for the preparation and presentation of the application for authorisation of health claims consistent criteria for the potential sources of scientific data. Such sources may not be available for all health claims. Nevertheless it will be relevant and important that EFSA comments on the availability and quality of such data in order to allow the regulator to judge and make a risk management decision about the acceptability of health claims included in the submitted list.

The scientific evidence about the role of a food on a nutritional or physiological function is not enough to justify the claim. The beneficial effect of the dietary intake has also to be demonstrated. Moreover, the beneficial effect should be significant i.e. satisfactorily demonstrate to beneficially affect identified functions in the body in a way which is relevant to health. Although an appreciation of the beneficial effect in relation to the nutritional status of the European population may be of interest, the presence or absence of the actual need for a nutrient or other substance with nutritional or physiological effect for that population should not, however, condition such considerations.

Different types of effects can be claimed. Claims referring to the maintenance of a function may be distinct from claims referring to the improvement of a function. EFSA may wish to comment whether such different claims comply with the criteria laid down in the Regulation.

WORDING OF HEALTH CLAIMS

Scientific substantiation of health claims is the main aspect on which EFSA's opinion is requested. However, the wording of health claims should also be commented by EFSA in its opinion.

There is potentially a plethora of expressions that may be used to convey the relationship between the food and the function. This may be due to commercial practices, consumer perception and linguistic or cultural differences across the EU. Nevertheless, the wording used to make health claims should be truthful, clear, reliable and useful to the consumer in choosing a healthy diet.

In addition to fulfilling the general principles and conditions of the Regulation laid down in Article 3 and 5, Article 13(1)(a) stipulates that health claims shall describe or refer to "the role of a nutrient or other substance in growth, development and the functions of the body". Therefore, the requirement to
describe or refer to the 'role' of a nutrient or substance in growth, development and the functions of the body should be carefully considered.

The specificity of the wording is very important. Health claims such as "Substance X supports the function of the joints" may not sufficiently do so, whereas a claim such as "Substance X helps maintain the flexibility of the joints" would. In the first example of a claim it is unclear which of the various functions of the joints is described or referred to contrary to the latter example which specifies this by using the word "flexibility".

The clarity of the wording is very important. The guiding principle should be that the description or reference to the role of the nutrient or other substance shall be clear and unambiguous and therefore be specified to the extent possible i.e. descriptive words/ terms which can have multiple meanings should be avoided. To this end, wordings like "strengthens your natural defences" or "contain antioxidants" should be considered as well as "may" or "might" as opposed to words like "contributes", "aids" or "helps".

In addition, for functions affected by a large number of dietary factors it should be considered whether wordings such as "indispensable", "necessary", "essential" and "important" reflects the strength of the scientific evidence.

Similar alternative wordings as mentioned above are used for claims relating to different relationships between the various foods and health. It is not the intention of the regulator to adopt a detailed and rigid list of claims where all possible wordings for the different claims are approved. Therefore, it is not required that EFSA comments on each individual wording for each claim unless the wording is strictly pertinent to a specific claim. It would be appreciated though that EFSA may consider and comment generally on such elements relating to wording to ensure the compliance with the criteria laid down in the Regulation.

In doing so the explanation provided for in recital 16 of the Regulation on the notion of the average consumer should be recalled. In addition, such assessment should take into account the particular perspective and/or knowledge in the target group of the claim, if such is indicated or implied.

**TERMS OF REFERENCE**

**HEALTH CLAIMS OTHER THAN THOSE REFERRING TO THE REDUCTION OF DISEASE RISK AND TO CHILDREN'S DEVELOPMENT AND HEALTH**

EFSA should in particular consider, and provide advice on the following aspects:

- Whether adequate information is provided on the characteristics of the food pertinent to the beneficial effect.

- Whether the beneficial effect of the food on the function is substantiated by generally accepted scientific evidence by taking into account the totality of the available scientific data, and by weighing the evidence. In this context EFSA is invited to comment on the nature and quality of the totality of the evidence provided according to consistent criteria.

- The specific importance of the food for the claimed effect. For functions affected by a large number of dietary factors whether a reference to a single food is scientifically pertinent.

In addition, EFSA should consider the claimed effect on the function, and provide advice on the extent to which:
β-Hydroxy β-methylbutyrate monohydrate (HMB) alone or in combination with α-ketoisocaproic acid (KIC) related health claims

- the claimed effect of the food in the identified function is beneficial.

- a cause and effect relationship has been established between consumption of the food and the claimed effect in humans and whether the magnitude of the effect is related to the quantity consumed.

- where appropriate, the effect on the function is significant in relation to the quantity of the food proposed to be consumed and if this quantity could reasonably be consumed as part of a balanced diet.

- the specific study group(s) in which the evidence was obtained is representative of the target population for which the claim is intended.

- the wordings used to express the claimed effect reflect the scientific evidence and complies with the criteria laid down in the Regulation.

When considering these elements EFSA should also provide advice, when appropriate:

- on the appropriate application of Article 10 (2) (c) and (d) in the Regulation, which provides for additional labelling requirements addressed to persons who should avoid using the food; and/or warnings for products that are likely to present a health risk if consumed to excess.
APPENDIX B

EFSA DISCLAIMER

The present opinion does not constitute, and cannot be construed as, an authorisation to the marketing of the food/food constituent, a positive assessment of its safety, nor a decision on whether the food/food constituent is, or is not, classified as foodstuffs. It should be noted that such an assessment is not foreseen in the framework of Regulation (EC) No 1924/2006.

It should also be highlighted that the scope, the proposed wordings of the claims and the conditions of use as proposed in the Consolidated List may be subject to changes, pending the outcome of the authorisation procedure foreseen in Article 13(3) of Regulation (EC) No 1924/2006.
APPENDIX C

Table 1. Main entry health claims related to β-hydroxy β-methylbutyrate monohydrate, either alone or in combination with α-ketoisocaproic acid, including conditions of use from similar claims, as proposed in the Consolidated List.

<table>
<thead>
<tr>
<th>ID</th>
<th>Food or Food constituent</th>
<th>Health Relationship</th>
<th>Proposed wording</th>
</tr>
</thead>
<tbody>
<tr>
<td>1576</td>
<td>HMB (B-hydroxy B- methylbutyrate monohydrate)</td>
<td>Support exercise recovery</td>
<td>HMB helps to enhance muscle energetics and recuperation.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Clarification provided</td>
<td>HMB helps with muscle energetics and recuperation</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Muscle recovery: Decreases creatine phosphokinase and LDH response, showing HMB helps prevent exercise-induced muscle damage.</td>
<td></td>
</tr>
</tbody>
</table>

**Conditions of use**
- The product must contain at least 1 gram HMB per serving
- Claim to be used for foods for active individuals

<table>
<thead>
<tr>
<th>ID</th>
<th>Food or Food constituent</th>
<th>Health Relationship</th>
<th>Proposed wording</th>
</tr>
</thead>
<tbody>
<tr>
<td>1577</td>
<td>HMB (B-hydroxy B- methylbutyrate monohydrate)</td>
<td>Minimize muscle protein breakdown</td>
<td>HMB helps to reduce muscle protein breakdown following exercise</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Ingredient clinically shown to support protection of muscles from breakdown following exercise</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>HMB helps to reduce exercise-induced muscle tissue breakdown.</td>
</tr>
</tbody>
</table>

**Conditions of use**
- The product must contain at least 1 gram HMB per serving
- Claim to be used for foods for active individuals

<table>
<thead>
<tr>
<th>ID</th>
<th>Food or Food constituent</th>
<th>Health Relationship</th>
<th>Proposed wording</th>
</tr>
</thead>
<tbody>
<tr>
<td>1578</td>
<td>HMB (B-hydroxy B- methylbutyrate monohydrate)</td>
<td>Increasing strength</td>
<td>HMB supports strength</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>HMB has been shown to increase strength.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>HMB has the ability to enhance muscular strength</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Ingredient clinically shown to help boost strength</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Boost muscular strength</td>
</tr>
</tbody>
</table>

**Conditions of use**
- The product must contain at least 1 gram HMB per serving
- Claim to be used for foods for active individuals
### β-Hydroxy β-methylbutyrate monohydrate (HMB) alone or in combination with α-ketoisocaproic acid (KIC) related health claims

<table>
<thead>
<tr>
<th>ID</th>
<th>Food or Food constituent</th>
<th>Health Relationship</th>
<th>Proposed wording</th>
</tr>
</thead>
</table>
| 1579 | HMB (B-hydroxy B-methylbutyrate monohydrate) | Increasing Mass | Supplementing with HMB may help improve body composition  
HMB supports maintenance of lean muscle mass  
With proper diet and exercise, HMB can help support an increase in fat free mass.  
HMB has been shown to increase lean muscle mass |

**Conditions of use**
- The product must contain at least 1 gram HMB per serving  
Claim to be used for foods for active individuals

<table>
<thead>
<tr>
<th>ID</th>
<th>Food or Food constituent</th>
<th>Health Relationship</th>
<th>Proposed wording</th>
</tr>
</thead>
<tbody>
<tr>
<td>1580</td>
<td>HMB (B-hydroxy B-methylbutyrate monohydrate)</td>
<td>Increasing exercise lactate threshold and VO2 peak</td>
<td>HMB may help increase the onset of blood lactate accumulation and VO2 peak.</td>
</tr>
</tbody>
</table>

**Conditions of use**
- The product must contain at least 1 gram HMB per serving  
Claim to be used for foods for active individuals

<table>
<thead>
<tr>
<th>ID</th>
<th>Food or Food constituent</th>
<th>Health Relationship</th>
<th>Proposed wording</th>
</tr>
</thead>
</table>
| 1581 | HMB | HMB and aerobic metabolism  
Clarity provided  
HMB increases VO2 max to a greater extent than training alone when used in conjunction with a cardiovascular training programme | HMB supplementation aids aerobic metabolism in endurance athletes, such as cyclists and runners |

**Conditions of use**
- Minimum of 3g per day for 2 weeks (3)

<table>
<thead>
<tr>
<th>ID</th>
<th>Food or Food constituent</th>
<th>Health Relationship</th>
<th>Proposed wording</th>
</tr>
</thead>
<tbody>
<tr>
<td>1582</td>
<td>HMB</td>
<td>HMB and lean body mass</td>
<td>HMB can increase gains in lean body mass during resistance training</td>
</tr>
</tbody>
</table>

**Conditions of use**
- Minimum of 3g HMB per day for 2 weeks combined with resistance training (10)

<table>
<thead>
<tr>
<th>ID</th>
<th>Food or Food constituent</th>
<th>Health Relationship</th>
<th>Proposed wording</th>
</tr>
</thead>
<tbody>
<tr>
<td>1583</td>
<td>HMB</td>
<td>HMB and training adaptations</td>
<td>HMB can improve body adaptation to intense training</td>
</tr>
</tbody>
</table>
**Clarification provided**

Body adaptation to training:
Increase lean body mass and muscle strength during a weight-training program.

### Conditions of use

- Minimum of 1.5g per day 2 weeks (10)

<table>
<thead>
<tr>
<th>ID</th>
<th>Food or Food constituent</th>
<th>Health Relationship</th>
<th>Proposed wording</th>
</tr>
</thead>
<tbody>
<tr>
<td>1584</td>
<td>HMB and HMB/KIC combinations</td>
<td>HMB and exercise induced muscle breakdown</td>
<td>HMB supplementation can reduce muscle breakdown after intense training. HMB reduces the loss of muscle proteins after intense training</td>
</tr>
</tbody>
</table>

### Conditions of use

- Minimum of 3g per day HMB and 0.3g KIC daily for 2 weeks (1)

<table>
<thead>
<tr>
<th>ID</th>
<th>Food or Food constituent</th>
<th>Health Relationship</th>
<th>Proposed wording</th>
</tr>
</thead>
<tbody>
<tr>
<td>1585</td>
<td>HMB and HMB/KIC combinations</td>
<td>HMB and muscle recovery after training</td>
<td>HMB supplementation supports muscle recovery after training</td>
</tr>
</tbody>
</table>

### Conditions of use

- Minimum of 3g per day HMB and 0.3g KIC daily for 2 weeks (1)

<table>
<thead>
<tr>
<th>ID</th>
<th>Food or Food constituent</th>
<th>Health Relationship</th>
<th>Proposed wording</th>
</tr>
</thead>
<tbody>
<tr>
<td>1586</td>
<td>HMB and HMB/KIC combinations</td>
<td>HMB and normal muscle repair</td>
<td>HMB supplementation maintains normal muscle repair after training</td>
</tr>
</tbody>
</table>

### Conditions of use

- Minimum of 3g per day HMB and 0.3g KIC daily for 2 weeks (1)

<table>
<thead>
<tr>
<th>ID</th>
<th>Food or Food constituent</th>
<th>Health Relationship</th>
<th>Proposed wording</th>
</tr>
</thead>
<tbody>
<tr>
<td>1587</td>
<td>HMB and HMB/KIC combinations</td>
<td>HMB and changes in muscle strength during training</td>
<td>HMB increases muscle strength when taken during a resistance training program.</td>
</tr>
</tbody>
</table>

### Conditions of use

- Minimum of 3g per day HMB and 0.3g KIC daily for 2 weeks (1) taken in conjunction with resistance training.
GLOSSARY AND ABBREVIATIONS

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>BIA</td>
<td>Bioelectrical impedance analysis</td>
</tr>
<tr>
<td>CK</td>
<td>Creatine kinase</td>
</tr>
<tr>
<td>DOMS</td>
<td>Delayed onset muscle soreness</td>
</tr>
<tr>
<td>DXA</td>
<td>Dual-energy x-ray absorptiometry</td>
</tr>
<tr>
<td>HMB</td>
<td>β-hydroxy β-methylbutyric acid</td>
</tr>
<tr>
<td>KIC</td>
<td>α-ketoisocaproic acid</td>
</tr>
<tr>
<td>LDH</td>
<td>Lactate dehydrogenase</td>
</tr>
<tr>
<td>RCT</td>
<td>Randomised controlled trial</td>
</tr>
<tr>
<td>RM</td>
<td>Repetition maximum</td>
</tr>
<tr>
<td>ROM</td>
<td>Range of motion</td>
</tr>
<tr>
<td>TOBEC</td>
<td>Total body electrical conductivity</td>
</tr>
</tbody>
</table>